New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe
Analysis shows greater pharmacist prescribing authority dramatically improves patient access
According to previous research, only 25% of those eligible for PrEP actually receive it, despite its strong efficacy. This lack of access, coupled with the ability to see the effect of state policies over multiple years, makes PrEP a valuable case study indicating that pharmacist prescribing power can improve access to prescription medications. A few states currently allow pharmacists to prescribe other medications, including birth control, smoking cessation medications, and medications for conditions such as asthma and diabetes.
“When access improves, as we saw with this study, so does adherence,” said
Key takeaways include:
- Expanding pharmacist prescriber authority for HIV PrEP medications significantly increased PrEP use.
PrEP fills grew 24% after 1 year and 110% after 2 years in states that passed pharmacist prescriber policies for PrEP, including
Colorado, California, Maine, Nevada, Oregon, and Virginia.
- Over 37 million people live in an under-resourced area. Expanding pharmacist prescriber authority in these areas could boost access to healthcare.
To learn more, please find the report here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the benefits of policies that expand pharmacists’ prescribing authority. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our acquisition strategy, the integration of acquired business and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended